HETEROCYCLIC COMPOUND Application WO-2024033845-A1 World Intellectual Property Organisation (WIPO) 15 Feb 2024
DOSING REGIMEN FOR A NLRP3 INHIBITOR Application WO-2024023696-A1 World Intellectual Property Organisation (WIPO) 01 Feb 2024
Protection of cells from degeneration and treatment of geographic atrophy Grant US-11883409-B2 United States of America 30 Jan 2024
Sulfonylureas and related compounds and use of same Grant US-11858922-B2 United States of America 02 Jan 2024
FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS Application WO-2023194964-A1 World Intellectual Property Organisation (WIPO) 12 Oct 2023
Protection of cells from degeneration and treatment of geographic atrophy Grant US-11730743-B2 United States of America 22 Aug 2023
Compounds and compositions for treating conditions associated with NLRP activity Grant US-11724992-B2 United States of America 15 Aug 2023
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives Grant US-11618751-B1 United States of America 04 Apr 2023
Sulphonyl urea derivatives as NLRP3 inflammasome modulators Grant US-11518757-B2 United States of America 06 Dec 2022
A FACILE AND ODOR-FREE APPROACH TO CONVERT SULFONYL UREA DERIVATIVES TO CHALCOGENIDE… Application WO-2022245627-A1 World Intellectual Property Organisation (WIPO) 24 Nov 2022
Compounds and compositions for treating conditions associated with NLRP activity Grant US-11447460-B2 United States of America 20 Sep 2022
Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors Grant US-11370776-B2 United States of America 28 Jun 2022
Urea derivatives and methods of use thereof Grant US-11345669-B2 United States of America 31 May 2022
Compounds and compositions for inhibiting retinal pigment epithelium degeneration and… Grant US-11260048-B2 United States of America 01 Mar 2022
Compounds and compositions for treating conditions associated with NLRP activity Grant US-11203579-B2 United States of America 21 Dec 2021
MODULATORS OF PURINERGIC RECEPTORS AND RELATED IMMUNE CHECKPOINT FOR TREATING ACUTE… Application WO-2021245107-A2 World Intellectual Property Organisation (WIPO) 09 Dec 2021
Sulfonylureas and related compounds and use of same Grant US-11130731-B2 United States of America 28 Sep 2021
TREATMENT AND PREVENTION OF NEUROINFLAMMATION OR AN INFLAMMATORY BRAIN DISORDER Application WO-2021089769-A1 World Intellectual Property Organisation (WIPO) 14 May 2021
Therapeutic methods involving modulating inflammasome activation of myeloid-derived… Grant US-10894061-B2 United States of America 19 Jan 2021
NLRP3 inhibitors for the treatment of inflammatory skin disorders Grant US-10857123-B2 United States of America 08 Dec 2020
METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT… Application WO-2020212484-A1 World Intellectual Property Organisation (WIPO) 22 Oct 2020
Compounds and compositions for treating conditions associated with NLRP activity Grant US-10654816-B2 United States of America 19 May 2020
BISPECIFIC ANTIBODY TARGETING IL-1R1 AND NLPR3 Application WO-2020053446-A1 World Intellectual Property Organisation (WIPO) 19 Mar 2020
Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors Grant US-10570157-B2 United States of America 25 Feb 2020
NLRP MODULATORS Application WO-2020010140-A1 World Intellectual Property Organisation (WIPO) 09 Jan 2020
SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS Application WO-2019121691-A1 World Intellectual Property Organisation (WIPO) 27 Jun 2019
CHEMICAL COMPOUNDS Application WO-2018167468-A1 World Intellectual Property Organisation (WIPO) 20 Sep 2018
Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development Grant US-10041044-B2 United States of America 07 Aug 2018
NLRP3 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS Application WO-2017129897-A1 World Intellectual Property Organisation (WIPO) 03 Aug 2017
Inhibitors nlrp3 for the treatment of pathologies cutaneous inflammatory Application FR-3046933-A1 France 28 Jul 2017
CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS Application WO-2017017469-A1 World Intellectual Property Organisation (WIPO) 02 Feb 2017